348 related articles for article (PubMed ID: 29190316)
1. Utility of initial induction chemotherapy with 5-fluorouracil, cisplatin, and docetaxel (DCF) for T4 esophageal cancer: a propensity score-matched analysis.
Makino T; Yamasaki M; Miyazaki Y; Wada N; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29190316
[TBL] [Abstract][Full Text] [Related]
2. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
[TBL] [Abstract][Full Text] [Related]
3. The Benefits of Docetaxel Plus Cisplatin and 5-Fluorouracil Induction Therapy in Conversion to Curative Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma.
Takeuchi M; Kawakubo H; Mayanagi S; Yoshida K; Irino T; Fukuda K; Nakamura R; Wada N; Takeuchi H; Kitagawa Y
World J Surg; 2019 Aug; 43(8):2006-2015. PubMed ID: 30972432
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma.
Miyawaki Y; Nakajima Y; Kawada K; Okada T; Tokairin Y; Kawano T
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27001629
[TBL] [Abstract][Full Text] [Related]
5. Concurrent cisplatin and 5-fluorouracil versus concurrent cisplatin and docetaxel with radiotherapy for esophageal squamous cell carcinoma: a propensity score-matched analysis.
Zhang P; Xi M; Li QQ; Hu YH; Guo X; Zhao L; Liu H; Liu SL; Luo LL; Liu Q; Liu MZ
Oncotarget; 2016 Jul; 7(28):44686-44694. PubMed ID: 27183916
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis.
Yamashita K; Katada N; Moriya H; Hosoda K; Mieno H; Katada C; Koizumi W; Hoshi K; Watanabe M
Gen Thorac Cardiovasc Surg; 2016 Apr; 64(4):209-15. PubMed ID: 26868531
[TBL] [Abstract][Full Text] [Related]
7. Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003).
Yamasaki M; Yasuda T; Yano M; Hirao M; Kobayashi K; Fujitani K; Tamura S; Kimura Y; Miyata H; Motoori M; Shiraishi O; Makino T; Satoh T; Mori M; Doki Y
Ann Oncol; 2017 Jan; 28(1):116-120. PubMed ID: 27687307
[TBL] [Abstract][Full Text] [Related]
8. The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma.
Hiyoshi Y; Yoshida N; Watanabe M; Kurashige J; Baba Y; Sakamoto Y; Baba H
World J Surg; 2017 Feb; 41(2):480-486. PubMed ID: 27637603
[TBL] [Abstract][Full Text] [Related]
9. Role of definitive chemoradiotherapy using docetaxel and 5-fluorouracil in patients with unresectable locally advanced esophageal squamous cell carcinoma: a phase II study.
Hihara J; Hamai Y; Emi M; Murakami Y; Kenjo M; Nagata Y; Okada M
Dis Esophagus; 2016 Nov; 29(8):1115-1120. PubMed ID: 26471962
[TBL] [Abstract][Full Text] [Related]
10. Utility of weekly docetaxel combined with preoperative radiotherapy for locally advanced esophageal cancer from pathological analysis.
Kushida T; Nohara S; Yoshino K; Fujiwara D; Ouchi K; Amano T; Isayama F; Tomita N; Iwanuma Y; Sasai K; Tsurumaru M; Kajiyama Y
Dis Esophagus; 2014; 27(4):368-73. PubMed ID: 23865505
[TBL] [Abstract][Full Text] [Related]
11. Induction chemoradiotherapy including docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal cancer.
Hashimoto M; Shirakawa Y; Maeda N; Tanabe S; Noma K; Sakurama K; Katsui K; Nishizaki M; Fujiwara T
Esophagus; 2020 Apr; 17(2):127-134. PubMed ID: 31897761
[TBL] [Abstract][Full Text] [Related]
12. Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2).
Higuchi K; Komori S; Tanabe S; Katada C; Azuma M; Ishiyama H; Sasaki T; Ishido K; Katada N; Hayakawa K; Koizumi W;
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):872-9. PubMed ID: 24867539
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence.
Yamashita K; Hosoda K; Moriya H; Katada C; Sugawara M; Mieno H; Komori S; Katada N; Watanabe M
Oncology; 2017; 92(4):221-228. PubMed ID: 28110330
[TBL] [Abstract][Full Text] [Related]
15. Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy.
Xi M; Zhang P; Zhang L; Yang YD; Liu SL; Li Y; Fu JH; Liu MZ
Jpn J Clin Oncol; 2017 Aug; 47(8):683-689. PubMed ID: 28453815
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Triplet Chemotherapy with Docetaxel, Cisplatin plus 5-Fluorouracil versus Docetaxel, Cisplatin plus S-1 for Advanced Esophageal Squamous cell Carcinoma: Propensity Score Matched Analysis.
Kitadani J; Ojima T; Hayata K; Goda T; Takeuchi A; Tominaga S; Fukuda N; Nakai T; Yamaue H; Kawai M
Oncology; 2024; 102(3):228-238. PubMed ID: 37708864
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus.
Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Kato T; Kitadani J; Tabata H; Takeuchi A; Iwahashi M; Yamaue H
Anticancer Res; 2016 Feb; 36(2):829-34. PubMed ID: 26851048
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy for locally advanced esophageal cancer comparing cisplatin and 5-fluorouracil versus docetaxel plus cisplatin and 5-fluorouracil: a propensity score matching analysis.
Nishiwaki N; Noma K; Kunitomo T; Hashimoto M; Maeda N; Tanabe S; Sakurama K; Shirakawa Y; Fujiwara T
Esophagus; 2022 Oct; 19(4):626-638. PubMed ID: 35792947
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.
Koo DH; Park SI; Kim YH; Kim JH; Jung HY; Lee GH; Choi KD; Song HJ; Song HY; Shin JH; Cho KJ; Yoon DH; Kim SB
Cancer Chemother Pharmacol; 2012 Mar; 69(3):655-63. PubMed ID: 21968953
[TBL] [Abstract][Full Text] [Related]
20. [Comparison between docetaxel plus cisplatin and cisplatin plus fluorouracil in the neoadjuvant chemoradiotherapy for local advanced esophageal squamous cell carcinoma].
Wu S; Chen MY; Luo JC; Wei L; Chen Z
Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):873-6. PubMed ID: 23291141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
